Literature DB >> 26962068

Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity.

Lindsay I Berrigan1, John D Fisk2, Scott B Patten2, Helen Tremlett2, Christina Wolfson2, Sharon Warren2, Kirsten M Fiest2, Kyla A McKay2, Ruth Ann Marrie2.   

Abstract

OBJECTIVE: To evaluate the direct and indirect influences of physical comorbidity, symptoms of depression and anxiety, fatigue, and disability on health-related quality of life (HRQoL) in persons with multiple sclerosis (MS).
METHODS: A large (n = 949) sample of adults with MS was recruited from 4 Canadian MS clinics. HRQoL was assessed using the patient-reported Health Utilities Index Mark 3. Expanded Disability Status Scale scores, physical comorbidity, depression, anxiety, and fatigue were evaluated as predictors of HRQoL in a cross-sectional path analysis.
RESULTS: All predictors were significantly associated with HRQoL and together accounted for a large proportion of variance (63%). Overall, disability status most strongly affected HRQoL (β = -0.52) but it was closely followed by depressive symptoms (β = -0.50). The direct associations of physical comorbidity and anxiety with HRQoL were small (β = -0.08 and -0.10, respectively), but these associations were stronger when indirect effects through other variables (depression, fatigue) were also considered (physical comorbidity: β = -0.20; anxiety: β = -0.34).
CONCLUSIONS: Increased disability, depression and anxiety symptoms, fatigue, and physical comorbidity are associated with decreased HRQoL in MS. Disability most strongly diminishes HRQoL and, thus, interventions that reduce disability are expected to yield the most substantial improvement in HRQoL. Yet, interventions targeting other factors amenable to change, particularly depression but also anxiety, fatigue, and physical comorbidities, may all result in meaningful improvements in HRQoL, as well. Our findings point to the importance of further research confirming the efficacy of such interventions.
© 2016 American Academy of Neurology.

Entities:  

Year:  2016        PMID: 26962068      PMCID: PMC4831037          DOI: 10.1212/WNL.0000000000002564

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  33 in total

Review 1.  Causes and consequences of comorbidity: a review.

Authors:  R Gijsen; N Hoeymans; F G Schellevis; D Ruwaard; W A Satariano; G A van den Bos
Journal:  J Clin Epidemiol       Date:  2001-07       Impact factor: 6.437

2.  Type D, anxiety and depression in association with quality of life in patients with Parkinson's disease and patients with multiple sclerosis.

Authors:  Tatiana Dubayova; Martina Krokavcova; Iveta Nagyova; Jaroslav Rosenberger; Zuzana Gdovinova; Berrie Middel; Johan W Groothoff; Jitse P van Dijk
Journal:  Qual Life Res       Date:  2012-10-11       Impact factor: 4.147

3.  Factors predicting quality of life in a group of Polish subjects with multiple sclerosis: accounting for functional state, socio-demographic and clinical factors.

Authors:  Ewa Papuć; Zbigniew Stelmasiak
Journal:  Clin Neurol Neurosurg       Date:  2011-12-01       Impact factor: 1.876

4.  Validation of the Hospital Anxiety and Depression Scale for use with multiple sclerosis patients.

Authors:  Kimia Honarmand; Anthony Feinstein
Journal:  Mult Scler       Date:  2009-11-13       Impact factor: 6.312

5.  Multiple sclerosis and bipolar disorders: the burden of comorbidity and its consequences on quality of life.

Authors:  M G Carta; M F Moro; L Lorefice; A Picardi; G Trincas; G Fenu; E Cocco; F Floris; D Bessonov; H S Akiskal; M G Marrosu
Journal:  J Affect Disord       Date:  2014-06-02       Impact factor: 4.839

6.  Physical activity and quality of life in multiple sclerosis: intermediary roles of disability, fatigue, mood, pain, self-efficacy and social support.

Authors:  Robert W Motl; Edward McAuley; Erin M Snook; Rachael C Gliottoni
Journal:  Psychol Health Med       Date:  2009-01       Impact factor: 2.423

7.  Construction and validation of a fatigue impact scale for daily administration (D-FIS).

Authors:  John D Fisk; Susan E Doble
Journal:  Qual Life Res       Date:  2002-05       Impact factor: 4.147

8.  Quality of life in people with multiple sclerosis: data from the Sonya Slifka Longitudinal Multiple Sclerosis Study.

Authors:  Ning Wu; Sarah L Minden; David C Hoaglin; Louise Hadden; Debra Frankel
Journal:  J Health Hum Serv Adm       Date:  2007

9.  Anxiety and depression influence the relation between disability status and quality of life in multiple sclerosis.

Authors:  A C J W Janssens; P A van Doorn; J B de Boer; N F Kalkers; F G A van der Meche; J Passchier; R Q Hintzen
Journal:  Mult Scler       Date:  2003-08       Impact factor: 6.312

10.  Change in quality of life and predictors of change among patients with multiple sclerosis: a prospective cohort study.

Authors:  Darija Kisic Tepavcevic; Tatjana Pekmezovic; Nebojsa Stojsavljevic; Jelena Kostic; Irena Dujmovic Basuroski; Sarlota Mesaros; Jelena Drulovic
Journal:  Qual Life Res       Date:  2013-10-01       Impact factor: 4.147

View more
  40 in total

1.  Change and onset-type differences in the prevalence of comorbidities in people with multiple sclerosis.

Authors:  Lara Marie Pangan Lo; Bruce V Taylor; Tania Winzenberg; Andrew J Palmer; Leigh Blizzard; Ingrid van der Mei
Journal:  J Neurol       Date:  2020-09-03       Impact factor: 4.849

2.  Estimating the relative contribution of comorbidities in predicting health-related quality of life of people with multiple sclerosis.

Authors:  Lara Marie Pangan Lo; Bruce V Taylor; Tania Winzenberg; Andrew J Palmer; Leigh Blizzard; Hasnat Ahmad; Mohammad Akhtar Hussain; Ingrid van der Mei
Journal:  J Neurol       Date:  2020-09-02       Impact factor: 4.849

Review 3.  Mental Health Comorbidity in MS: Depression, Anxiety, and Bipolar Disorder.

Authors:  Aaron P Turner; Kevin N Alschuler; Abbey J Hughes; Meghan Beier; Jodie K Haselkorn; Alicia P Sloan; Dawn M Ehde
Journal:  Curr Neurol Neurosci Rep       Date:  2016-12       Impact factor: 5.081

4.  Psychiatric comorbidity is associated with disability progression in multiple sclerosis.

Authors:  Kyla A McKay; Helen Tremlett; John D Fisk; Tingting Zhang; Scott B Patten; Lorne Kastrukoff; Trudy Campbell; Ruth Ann Marrie
Journal:  Neurology       Date:  2018-03-09       Impact factor: 9.910

5.  Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale.

Authors:  Myla D Goldman; Melanie D Ward; Robert W Motl; David E Jones; John H Pula; Diego Cadavid
Journal:  Mult Scler       Date:  2016-12-07       Impact factor: 6.312

6.  The 27-Item Multiple Sclerosis Quality of Life Questionnaire: A New Brief Measure Including Treatment Burden and Work Life.

Authors:  Helen Beckmann; Christoph Heesen; Matthias Augustin; Christine Blome
Journal:  Int J MS Care       Date:  2021-12-07

7.  Physical and Mental Health-Related Quality of Life Trajectories Among People With Multiple Sclerosis.

Authors:  Julia O'Mahony; Amber Salter; Beyza Ciftci; Robert J Fox; Gary R Cutter; Ruth Ann Marrie
Journal:  Neurology       Date:  2022-08-10       Impact factor: 11.800

8.  Ten-year follow-up of health-related quality of life among ambulatory persons with multiple sclerosis at baseline.

Authors:  Aki Rintala; Arja Häkkinen; Jaana Paltamaa
Journal:  Qual Life Res       Date:  2016-06-30       Impact factor: 4.147

9.  The prevalence of comorbidities in patients with multiple sclerosis: population-based registry data.

Authors:  Gorica D Maric; Tatjana D Pekmezovic; Sarlota T Mesaros; Olivera S Tamas; Jovana B Ivanovic; Vanja N Martinovic; Marko M Andabaka; Aleksa Lj Jovanovic; Nikola D Veselinovic; Darija B Kisic-Tepavcevic; Jelena S Drulovic
Journal:  Neurol Sci       Date:  2020-09-22       Impact factor: 3.307

10.  Influence of Comorbidities on Healthcare Expenditures and Perceived Physical and Mental Health Status Among Adults with Multiple Sclerosis: A Propensity Score-Matched US National-Level Study.

Authors:  Sandipan Bhattacharjee; Zufan Yegezu; Kristin Kollecas; Kevin Duhrkopf; Lobat Hashemi; Nupur Greene
Journal:  Clinicoecon Outcomes Res       Date:  2021-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.